ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 0984 • ACR Convergence 2022

    Impact of Hydroxychloroquine on Interferon Pathway Expression of SLE Phenotypic Subsets in the Absence of Background Medications

    Colin Mowery, Miles Smith, Kevin Thomas, Susan Macwana, Wade deJager, Stan Kamp, Cristina Arriens, Teresa Aberle, Judith James, Joel Guthridge and Joan Merrill, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Chronic activation of interferon (IFN) pathways is a key driver of immune dysregulation in SLE. Hydroxychloroquine (HCQ) inhibits toll-like receptors 7 and 9 in…
  • Abstract Number: 1001 • ACR Convergence 2022

    Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)

    David Isenberg1, Celia Lin2, Amy Kao3, Aida Aydemir4 and Caroline Gordon5, 1University College London, London, United Kingdom, 2Vera Therapeutics, Inc, Burlingame, CA, 3EMD Serono, Billerica, MA, 4EMD Serono Research & Development Institute, Inc, Billerica, MA, 5Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

    Background/Purpose: Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferation-inducing ligand, which are increased in patients with SLE. APRIL-SLE was a double-blind,…
  • Abstract Number: 1193 • ACR Convergence 2022

    Seasonal Variation of Hospitalizations and In-Hospital Mortality Related to Systemic Lupus Erythematosus Among Adults in the United States: An Analysis of Nationwide Inpatient Sample

    Jiayi Zheng1, Ruoning Ni2, Guangchen Zou3, Qianlan Xi4, Tien-Chan Hsieh3 and Shahrzad Abdollahi5, 1The Wright Center for Graduate Medical Education, Scranton, PA, 2Ascension Saint Agnes Hospital, Iowa City, IA, 3Danbury Hospital, Danbury, CT, 4Memorial Hospital West, Pembroke Pines, FL, 5Division of Rheumatology, Lewis Katz School of Medicine, Temple University Hospital, Philadelphia, PA

    Background/Purpose: While the seasonal variation of systemic lupus erythematosus (SLE) disease activity has been reported, population-based studies are still lacking. Here we investigate the seasonal…
  • Abstract Number: 1369 • ACR Convergence 2022

    Sun Protection Use in Patients Followed in a Pediatric Rheumatology Clinic in an Urban Setting

    Tom Elena Dubov1, Dawn Wahezi2, Evin Rothschild2, Tamar Rubinstein3 and Tamara Tanner4, 1NYCH+H/Jacobi, Bronx, NY, 2Children's Hospital at Montefiore, Bronx, NY, 3Albert Einstein College of Medicine, White Plains, NY, 4Montefiore Medical Center, Bronx, NY

    Background/Purpose: Exposure to sunlight has been implicated as a major contributing factor in the pathogenesis of systemic lupus erythematosus (SLE) and juvenile dermatomyositis (JDM). Despite…
  • Abstract Number: 1446 • ACR Convergence 2022

    Contrast Enhaced Articular Magnetic Resonance Imaging (MRI) and Health Related Quality of Life in SLE Patients

    Tarek Carlos Salman-Monte1, Patricia Corzo2, Ivan Garcia-Duitama3, ANA Agustí Claramunt3, Irene Carrion Barbera4, Salvatore Marsico3 and Jordi Monfort5, 1Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Hospital del Mar, Radiology, Barcelona, Spain, 4Hospital del Mar, Rheumatology, Barcelona, Spain, 5Hospital del Mar, Barcelona, Spain

    Background/Purpose: Joint involvement in SLE is the most frequent manifestation and shows a wide heterogeneity (1) . It has not a valid classification and it…
  • Abstract Number: 1464 • ACR Convergence 2022

    Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations

    Ganiat Adeogun, Alex Camai, Sarah Green and April Barnado, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects females of reproductive age but can affect patients later in life. Late-onset (LO)-SLE is defined as SLE diagnosed…
  • Abstract Number: 1482 • ACR Convergence 2022

    Latent Tuberculosis Infection and Its Associations with Clinical and Serological Parameters in Systemic Lupus Erythematosus

    Gayathri MS1, Chengappa Kavadichanda2, Aishwarya Gopal3, Devender Bairwa4, Molly Thabah1, Sonali Sarkar5 and Prakash Babu Narasimhan1, 1Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, 2JIPMER, Pondicherry, Puducherry, India, 3Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, 4Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, 5Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

    Background/Purpose: Latent tuberculosis infection (L-TB) detected by mycobacterium tuberculosis (TB) IFN-γ release assay (TB-IGRA), besides identifying latent infection may predict the disease status in SLE.…
  • Abstract Number: 1664 • ACR Convergence 2022

    TRIM21 as a Regulator of UVB-Driven IFN Responses in Lupus

    Richard Moore, Gantsetseg Tumurkhuu, Daniel Wallace and Caroline Jefferies, Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) experience photosensitivity where exposure to ultraviolet light B (UVB) drives lupus flares and systemic symptoms. Although the mechanisms…
  • Abstract Number: 1723 • ACR Convergence 2022

    CXCR4-targeted Functionally Selective Immunomodulator Shows Robust Efficacy in Pristane-induced Murine Lupus Model

    Annegret Van der Aa1, Simon Tessier1, Jean-Philippe Herbeuval2 and Joël Crouzet1, 1Ermium Therapeutics SAS, Paris, France, 2CBMIT, CNRS UMR 8601, Université Paris Cité, Paris, France

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. There is still a high unmet need to improve current treatment options. The chemokine…
  • Abstract Number: 2053 • ACR Convergence 2022

    Current State and Completeness of Reporting Clinical Prediction Models Using Machine Learning in Systemic Lupus Erythematosus: A Systematic Review

    Claudia Mendoza-Pinto1, Ivet Etchegaray-Morales2, Pamela Munguía-Realpozo2, David Angel Osorio-Peña2, Socorro Méndez-Martínez1 and Mario Garcia-Carrasco2, 1Instituto Mexicano del Seguro Social, Puebla, Mexico, 2Benemérita Universidad Autónoma de Puebla, Puebla, Mexico

    Background/Purpose: There is increased interest in machine learning (ML)-based prediction models in systemic lupus erythematosus (SLE). We made a systematic review of adherence in diagnostic…
  • Abstract Number: 2070 • ACR Convergence 2022

    Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis

    Sarah Dyball1, John Reynolds2, Hector Chinoy3, Ariane Herrick1, Sahena Haque4, Ellen Bruce5, Sophia Naz6, Ben Parker7 and Ian N. Bruce8, 1The University of Manchester, Manchester, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3The University of Manchester, Sale, United Kingdom, 4Manchester Foundation Trust, Manchester, United Kingdom, 5Kellgren Centre for Rheumatology, Manchester, United Kingdom, 6Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, 7Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, 8Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Poor health-related quality of life (HR-QoL) is well recognised within patients with connective tissue diseases (CTD). We hypothesised that subgroups of patients across the…
  • Abstract Number: 2087 • ACR Convergence 2022

    Prospective Study of Clinical, Laboratory, and Patient-Reported Outcomes of Patients with Systemic Lupus Erythematosus Undergoing Total Hip and Total Knee Arthroplasty

    David Fernandez, Insa Mannstadt, Mark Figgie, Peter Sculco, Jason Blevins, Caroline Siegel, Deanna Jannat-Khah, DrPH, MSPH, Carey Ford, Mikhail Olferiev, Dina Greenman, Kyriakos Kirou and Susan Goodman, Hospital for Special Surgery, New York, NY

    Background/Purpose: Patients with SLE have doubled their utilization of THA and TKA, yet postoperative complications remain high. However, disease specific measures have not been assessed.…
  • Abstract Number: 2107 • ACR Convergence 2022

    Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus (SLE): Impact of Preexisting Hypertension

    azalfa Lateef1, stephanie Bray2, Dulaney Wilson2, Jim Oates2 and Diane Kamen2, 1MUSC, Columbia, SC, 2Medical University of South Carolina, Charleston, SC

    Background/Purpose: Advances in medicine for women with systemic lupus erythematosus (SLE) have led to improved pregnancy outcomes, but pregnancies are still high-risk and disparities remain.…
  • Abstract Number: PP10 • ACR Convergence 2022

    How Advocating for My Autoimmune Disease Led Me to Desire to Pursue a Career in Rheumatology

    Brooklyn Johnson1 and Kathleen Collins2, 1Memphis, TN, 2LeBonheur Children's Hospital, Memphis, TN

    Background/Purpose: The summer before my senior year, I developed a faint rash on my face and my arms. At a dermatology appointment, I pointed this…
  • Abstract Number: 0092 • ACR Convergence 2022

    Characterizing Levels of Specialist Care Received by Patients with Systemic Lupus Erythematosus: Clinical Characteristics, Emergency Care, Hospitalization, and Costs Among Commercially-insured Adults in the United States

    Sandra Sze-jung Wu1, Allison Perry2, Helen Varker3, Christine Dube1 and Gary Bryant4, 1AstraZeneca, Wilmington, DE, 2IBM Watson Health, Cambridge, MA, 3Merative, Cambridge, MA, 4AstraZeneca, New Castle, DE

    Background/Purpose: Heterogeneous SLE manifestations can delay referral and diagnosis by a rheumatologist (rheum) in as many as 75% of patients (pts) with SLE.1 After diagnosis,…
  • « Previous Page
  • 1
  • …
  • 94
  • 95
  • 96
  • 97
  • 98
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology